A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103 [EXTENSION OF 700240251]
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Aldafermin (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 23 Aug 2016 Status changed from recruiting to completed.
- 15 May 2014 New trial record